Genmab A/S (NASDAQ:GMAB) reported first-quarter 2026 results highlighting revenue growth, expanding proprietary product sales, and continued investment in its late-stage pipeline, while maintaining profitability....
Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in...
Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory...
Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review ...
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio ...
Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for...
Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2 ) resulted in statistically significant and clinically...
New two- and three-year EPCORE ® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL ...
Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based...